Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020

Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020

Objectives To evaluate the reporting rate of adverse events following immunization (AEFI) of the quadrivalent human papillomavirus vaccine (4vHPV) and to compare the reporting rate of AEFI following 4vHPV with those following other vaccines. Methods Review and describe the AEFI reported to national...

Full description

Bibliographic Details
Main Authors:	Yu Hu, Xuejiao Pan, Linzhi Shen, Fuxing Chen, Ying Wang, Hui Liang, Yaping Chen, Huakun Lv
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	aefi (adverse events following immunization) quadrivalent human papillomavirus vaccine surveillance vaccination safety
Online Access:	http://dx.doi.org/10.1080/21645515.2021.1978793

Similar Items

Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system
by: Xuejiao Pan, et al.
Published: (2021-10-01)

Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021
by: Fuxing Chen, et al.
Published: (2022-12-01)

Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China
by: Xuejiao Pan, et al.
Published: (2022-01-01)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
by: Yu Hu, et al.
Published: (2022-01-01)

Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine
by: Huakun Lv, et al.
Published: (2021-11-01)

Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022
by: Hui Liang, et al.
Published: (2025-01-01)

Surveillance on the adverse events following immunization in Dazu District of Chongqing， 2016‒2020
by: WANG Qian, et al.
Published: (2022-04-01)

Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community—Spain (2008–2018)
by: Cecilia M. Egoavil, et al.
Published: (2020-03-01)

Quadrivalent Human Papillomavirus Vaccine Effectiveness after 12 Years in Madrid (Spain)
by: Juan J. Hernandez-Aguado, et al.
Published: (2022-03-01)

Barriers to healthcare workers reporting adverse events following immunization in Zhejiang province, China
by: Huakun Lv, et al.
Published: (2022-11-01)

Adverse events following immunization surveillance on two types of enterovirus 71 vaccines: A real-world comparative study in China
by: Yiqing Zhu, et al.
Published: (2025-12-01)

Resolution of Harada disease-like uveitis after quadrivalent human papillomavirus vaccination: a case report
by: Kangjie Kong, et al.
Published: (2022-01-01)

A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
by: Huakun Lv, et al.
Published: (2022-02-01)

A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study
by: Mohamed Serhan, et al.
Published: (2024-12-01)

Safety assessment of seasonal trivalent influenza vaccine produced by Instituto Butantan from 2013 to 2017
by: Vera Lúcia Gattás, et al.
Published: (2018-12-01)

Influenza surveillance in Western Turkey in the era of quadrivalent vaccines: A 2003–2016 retrospective analysis
by: Sevim Meşe, et al.
Published: (2018-08-01)

Safety of Monkeypox Vaccine Using Active Surveillance, Two-Center Observational Study in Italy
by: Marco Montalti, et al.
Published: (2023-06-01)

Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa
by: AbdulAzeez Adeyemi Anjorin, et al.
Published: (2022-04-01)

Potential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, Australia
by: C.-M. Baxter, et al.
Published: (2018-08-01)

Does This COVID-19 Pandemic Demand a Scale Up in AEFI Reporting in India?
by: Sadhvika Kanagat, et al.
Published: (2022-09-01)

Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016)
by: Alexandre Blikstad Mauro, et al.

Knowledge, perceptions, and practice towards adverse events following immunization surveillance among vaccination workers in Zhejiang province, China
by: Huakun Lv, et al.
Published: (2023-01-01)

Adverse event reporting following immunization of hepatitis B vaccine: A 13-year review
by: Xiaoying Gong, et al.
Published: (2024-12-01)

The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01)

Intussusception and Other Adverse Event Surveillance after Pilot Introduction of Rotavirus Vaccine in Nam Dinh and Thua Thien Hue Provinces—Vietnam, 2017–2021
by: Ly Khanh Thi Le, et al.
Published: (2024-02-01)

Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy)
by: Pasquale Stefanizzi, et al.
Published: (2023-02-01)

Surveillance analysis of adverse events following immunization with the bivalent human papillomavirus vaccine and recombinant human papillomavirus 9-valent vaccine in Hebei province from 2018 to 2022
by: Jinghui WANG, et al.
Published: (2024-09-01)

Surveillance of adverse events following varicella vaccine immunization in Jiangsu province, China from 2017 to 2023
by: Lei Zhang, et al.
Published: (2024-09-01)

Postlicensure safety surveillance of congenital anomaly and miscarriage among pregnancies exposed to quadrivalent human papillomavirus vaccine
by: Lina S. Sy, et al.
Published: (2018-02-01)

Non-linear effects of age in reporting of adverse events following influenza immunization in Zhejiang, China
by: Fuxing Chen, et al.
Published: (2024-12-01)

Vaccine Safety International Monitoring
by: M. A. Darmostukova, et al.
Published: (2019-03-01)

INFLUENZA VACCINATION OF CHILDREN OF PRESCHOOL AGE IN THE RUSSIAN FEDERATION: COST-EFFECTIVENESS OF QUADRIVALENT VACCINE
by: A. V. Rudakova, et al.
Published: (2019-03-01)

Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort
by: Alltalents T. Murahwa, et al.
Published: (2024-01-01)

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations
by: Yunhua Wei, et al.
Published: (2022-11-01)

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study
by: Ingrid Herta Rotstein Grein, et al.
Published: (2020-11-01)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
by: Anna Fochesato, et al.
Published: (2022-08-01)

Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics’ impact
by: Ohoud A. Almadani, et al.
Published: (2022-12-01)

Current safety issues with quadrivalent meningococcal conjugate vaccines
by: Tanya R. Myers, et al.
Published: (2018-05-01)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
by: Filippo Rumi, et al.
Published: (2023-11-01)

Surveillance for adverse events following immunization in Hebei Province, China, 2018-2020
by: Li Sun, et al.
Published: (2024-12-01)